Research And Views Archives | Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

Archives... Don't Miss Anything, Ever!

Here you will find all the research and views that we post on Equitymaster. Use the tools to customize the results to suit your preference!


















Authors
 

WOCKHARDT Fact Sheet, WOCKHARDT Financial Results - Equitymaster

Jan 25, 2022 | Updated on Jan 25, 2022

Check out WOCKHARDT fact sheet and WOCKHARDT financial results online at Equitymaster.

WOCKHARDT Quarterly Results - Equitymaster

Jan 25, 2022 | Updated on Jan 25, 2022

Check out latest WOCKHARDT Quarterly Results online at Equitymaster.

WOCKHARDT Share price, NSE/BSE Forecast News and Quotes| Equitymaster

Jan 25, 2022 | Updated on Jan 25, 2022

WOCKHARDT: Get the latest WOCKHARDT Share price and stock price updates, live NSE/BSE share price, share market reports, financial report, balance sheet, price charts, financial forecast news and quotes only at Equitymaster.com.

5 Indian Pharma Companies Riding the Vaccination Wave

Sep 3, 2021

These companies are likely to benefit the most from Covid-19 vaccines.

CAROL INFO Share price, NSE/BSE Forecast News and Quotes| Equitymaster

Mar 9, 2012 | Updated on Mar 9, 2012

CAROL INFO: Get the latest CAROL INFO Share price and stock price updates, live NSE/BSE share price, share market reports, financial report, balance sheet, price charts, financial forecast news and quotes only at Equitymaster.com.

The curious case of Wockhardt - II

Jun 21, 2011

This series of 2 articles describes the fall of Wockhardt from its peak in 2008 and its current situation.

Wockhardt: Europe led 2004

Feb 10, 2005

Domestic pharma company, Wockhardt, recently declared its December quarter as well as full year numbers. In 4QCY04, the company's consolidated revenues clocked a buoyant 21% growth led by strong performance in Europe and rest of the world. Its bottomline growth was equally buoyant at 26% YoY. The company ended the full year with over 31% revenue and nearly 50% bottomline growth.

Wockhardt: Sustainability is the key

Oct 21, 2004

Domestic pharma company, Wockhardt, has declared its 3QCY04 and 9mCY04 results. In 3QCY04, the company's topline grew by 11.3% led by decent show of its European operations. The bottomline grew by 13.6%, basically led by expansion of operating margins by nearly 4%.

Pharma: Global Vs local

Jun 10, 2004

There are two types of companies in the Indian pharma industry. While some are subsidiaries of global giants, others are home grown companies. Glaxo, Pfizer, Aventis and Novartis fall in the former category, while Ranbaxy, Cipla, Dr Reddy's, Wockhardt and Nicholas Piramal fall in the latter. Let's compare their business models and their performance.

Wockhardt: The insulin story

Sep 23, 2003

In line with the general market sentiment, Wockhardt has been steadily gaining in the past few months. The key reason for this upswing in Wockhardt’s stock price has been the launch of human insulins (branded as ‘Wosulin’) by the company. Wockhardt has thus become Asia’s first and the world’s fourth producer of human recombinant insulin. But how big is this news and what could be its implications on the future revenues of the company. Let’s find out.

Wockhardt: Good times ahead

Aug 6, 2003

Domestic pharma major, Wockhardt has declared its 2QFY04 results recently. After witnessing a poor first quarter, the company has reported a marginal 5% increase in the topline and a 13% increase in the bottomline. For 1HFY04, the company has recorded a stagnant topline and a 20% drop in the bottomline. In this context, let us briefly examine the performance of the company during 2QFY04.

Wockhardt: Going international

Jul 15, 2003

Wockhardt Ltd, a subsidiary of Khorakiwala Holdings and Investments Pvt. Ltd, is one of the leading domestic pharmaceutical companies with strong presence in the lifestyle segment and growing focus on biotechnology. The company derives 62% of its revenues from the domestic markets. However, with the recent acquisitions in the international markets, the company has demonstrated its growing interest in exports. Wockhardt has also started increasing its R&D focus and has made investments of Rs 460

Wockhardt: Growing the inorganic way

Jul 10, 2003

Wockhardt is one of the leading domestic pharma companies with strong focus on the biotechnology sector for future growth. The company derives 62% of its revenues from the domestic market. However, off late, with increased competition and lower growth being witnessed in the domestic markets, Wockhardt has started to focus on exports. The company adopting the inorganic growth method for increasing exports had acquired Wallis Ltd in 1998.

Wockhardt: Swift growth

Oct 31, 2002

Wockhardt has posted another quarter of strong growth in revenues and improvement in operating margins. For 3QFY02, the company’s revenues were up 19%, while the bottomline grew by 22%.

Wockhardt: Swift progress

Jul 30, 2002

Wockhardt Ltd. has declared encouraging results for 1HFY03. While sales have grown by more than 20%, net profit forged ahead by 37%. The impressive performance in sales is on the back of strong growth in export formulations and key brands in the domestic market.

Wockhardt: Strong performance

Apr 29, 2002

Wockhardt Ltd. has declared encouraging results for 1QFY03. While sales have grown by more than 27%, net profit forged ahead by 37%. The impressive performance in sales is on the back of strong growth in export formulations and key brands in the domestic market. The peformance of the company is above our expectations of 20% growth.

Wockhardt: R&D picks momentum

Apr 2, 2002

Yesterday Wockhardt announced that the first molecule (WCK-771) from its research pipeline has entered in to Phase-I of clinical trials in India. WCK-771 is an anti-infective molecule used in the treatment of sepsis. The company has already started exploring opportunities for out licensing the molecule.

Wockhardt: On an expansion mode

Mar 9, 2002

Wockhardt, the Rs 6.5 bn biotech pioneer in India seems to be on a major expansion drive with a clear growth strategy. While the company seems to have missed out on the generics boom, the export strategy, going forward, seems quite clear. The company is aiming to create global class capacities in some niche product categories.

Wockhardt: Impressive performance

Feb 12, 2002

Wockhardt Ltd has declared encouraging results for FY02. While sales have grown by more than 16%, net profit forged ahead by 43% to more than a Rs 1 bn. This was mainly on the back of an impressive 300 basis points rise in operating margins. However, interest cost shot up considerably to Rs 38 m. On a consolidated basis, sales for the quarter grew by 14% to Rs 2 bn while profits grew by 37%.

Wockhardt: R&D efforts kick start

Nov 22, 2001

Recently, Wockhardt announced filing application for conducting clinical trials on its anti-infective molecule, WCK-771.The company’s R&D initiative started some four years back. Though at a very early stage these seem to be bearing fruit.


Become A Smarter Investor
In Just 5 Minutes

Multibagger Stock Guide 2022
Get our special report Multibagger Stocks Guide (2022 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

MARKET STATS